The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent pneumococcal vaccine, Prevenar 20, aimed at preventing invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in individuals aged 6 weeks to 18 years. This vaccine was previously approved for use in adults aged 18 and older.
The approval is supported by Phase III clinical data demonstrating the vaccine’s safety, tolerability, and immunogenicity in pediatric populations. Prevenar 20 has also secured similar pediatric approvals in Australia, Brazil, Canada, and the United States.- Flcube.com
